Skip to main content
OpenTrials
Completed

NCT Number: NCT02996279

Chorioamnionitis and Proinflammatory S100A12

Histologic chorioamnionitis (HCA) may lead to the fetal inflammatory response syndrome (FIRS) and increased levels of proinflammatory molecules.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Histologic chorioamnionitis (HCA) may lead to the fetal inflammatory response syndrome (FIRS). The aim of this pilot study was to evaluate S100A12, a marker of innate immune activation, in mothers with or without HCA and in their infants.

Concentrations of S100A12, Interleukin 6 (IL-6) and C-reactive protein (CRP) were evaluated in maternal, cord, and neonatal blood of very preterm infants. Histologic examinations of placentae and umbilical cords were performed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Preterm Birth

Exclusion criteria

Congenital Abnormalities

Treatment and study plan

Primary outcomes

  1. S100A12 in Presence of Maternal Chorioamnionitis

    Time frame: 1 Year

    Levels of S100A12 in Maternal, Cord and Neonatal Blood in the Presence or Absence of HCA

Sponsors and collaborators

Lead sponsor

Catholic University of the Sacred Heart

Other

Registry information

Official study title

Impact of Chorioamnionitis on Maternal and Fetal Levels of Proinflammatory S100A12

Acronym: S100A12

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Dec 19, 2016
Registry last updated
Dec 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.